Año 2016 / Volumen 108 / Número 3
Original
Initial experience with golimumab in clinical practice for ulcerative colitis

129-132

DOI: 10.17235/reed.2016.4068/2015

Luisa Castro Laria, Federico Argüelles Arias, Valle García Sánchez, José Manuel Benítez, Ramón Fernández Pérez, Ana María Trapero Fernández, Francisco Gallardo Sánchez, Héctor Pallarés Manrique, María Gómez García, María José Cabello Tapia, Aurora Talavera Fabuel, Ana Bejarano García, Eduardo Leo Carnerero, Álvaro Hernández Martínez, Ángel Caunedo Álvarez, Juan Manuel Herrerías-Gutiérrez,

Resumen
Background: Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis. Purpose: To research the effectiveness and safety of golimumab in patients with ulcerative colitis in clinical practice. Methods: Retrospective study of the effectiveness and safety of golimumab in patients with ulcerative colitis. All patients received golimumab 200 mg subcutaneously at week 0, and golimumab 100 mg subcutaneously at week 2. After the induction treatment, each patient received 50 mg sc. every 4 weeks in patients with body weight less than 80 kg, and 100 mg every 4 weeks in patients with body weight greater than or equal to 80 kg. Results: Study of a group of 23 ulcerative colitis patients, 7 of whom were naive to any anti-TNF therapy, and 16 patients who had previously been treated with an anti-TNF agent other than golimumab (non-naive patients). The average treatment time with golimumab was 14.3 weeks. Globally, withdrawal of corticosteroids was observed in 74% of cases. Clinical response was observed in 85.5% of patients who had not received biological treatment previously, and in patients who had previously received biological treatment the response rate was 75%. Conclusions: In this short study, golimumab seems to be an alternative treatment in naive and non-naive anti-TNF ulcerative colitis patients. It is also a safe therapy, given that there were no adverse effects in the patients studied.
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. J Crohns Colitis 2012; 6: 965-90.
2. Lv R, Qiao W, Wu Z, et al. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PloS One 2014; 9: e86692.
3. Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014; 39: 660-71.
4. Simponi Summary of Product Characteristics [Online, 27 January 2015]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000992/WC500052368.pdf
5. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(Suppl A): 5A - 36A.
6. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
7. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. J Crohns Colitis 2012; 6: 991-1030.
8. Ng SD, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis 2009; 15: 935-50.
9. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2014; 146: 85-95.
10. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2014; 146: 96-109.e1.
11. Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015; 41: 613-623.
12. Curkovic I, Egbring M, Kullak-Ublick GA. Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates. Dig Dis Basel Switz 2013; 31: 368-73.
13. Garcia-Planella E, Mañosa M, Van Domselaar M, et al. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig Liver Dis 2012; 44: 206-10.
14. Zampeli E, Gizis M, Siakavellas SI, et al. Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World J Gastrointest Pathophysiol 2014; 5: 293-303.
15. Afzali A, Fausel R. Biologics in the management of ulcerative colitis -comparative safety and efficacy of TNF-alpha antagonists. Ther Clin Risk Manag 2015; 63.
16. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014; 13: 24-30.
17. Kevans D, Waterman M, Milgrom R, et al. Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis. J Gastroenterol Hepatol 2015; 30: 64-70.
18. Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol WJG 2014; 20: 3146-52.
19. Panaccione R, Ghosh S, Middleton S, et al. Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis. Gastroenterology 2014; 146: 392-400.
Artículos relacionados

Carta

Broadening perspectives in the treatment of chronic pouchitis

DOI: 10.17235/reed.2024.10865/2024

Carta

Ulcerative colitis complicated with hypermucinous dysplasia

DOI: 10.17235/reed.2024.10348/2024

Carta

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Revisión

Research progress in the combined treatment of ulcerative colitis

DOI: 10.17235/reed.2023.9444/2022

Carta

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Carta

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Carta

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Revisión

Escenarios clínicos con tofacitinib en colitis ulcerosa

DOI: 10.17235/reed.2022.8660/2022

Carta

Neumonitis intersticial por mesalazina en la era COVID

DOI: 10.17235/reed.2022.8635/2021

Carta

Efecto del Adacolumn® en colitis ulcerosa con COVID-19

DOI: 10.17235/reed.2020.7156/2020

Carta

Síndrome de Sweet en el brote grave de colitis ulcerosa

DOI: 10.17235/reed.2020.6995/2020

Carta al Editor

Colitis ulcerosa con afectación gástrica y duodenal

DOI: 10.17235/reed.2017.4685/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Caso Clínico

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Instrucciones para citar
Castro Laria L, Argüelles Arias F, García Sánchez V, Benítez J, Fernández Pérez R, Trapero Fernández A, et all. Initial experience with golimumab in clinical practice for ulcerative colitis. 4068/2015


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 892 veces.
Este artículo ha sido descargado 129 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 24/10/2015

Aceptado: 22/12/2015

Prepublicado: 20/01/2016

Publicado: 26/02/2016

Tiempo de revisión del artículo: 49 días

Tiempo de prepublicación: 88 días

Tiempo de edición del artículo: 125 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2025 y Creative Commons. Revista Española de Enfermedades Digestivas